Opendata, web and dolomites

EPI-X4Health SIGNED

Therapeutic potential of optimized derivatives of an endogenous CXCR4 antagonist for the treatment of cancers and inflammatory diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EPI-X4Health project word cloud

Explore the words cloud of the EPI-X4Health project. It provides you a very rough idea of what is the project "EPI-X4Health" about.

potent    therapeutic    diseases    blood    mouse    strategy    libraries    hiv    experimental    clinical    serum    agents    compounds    exists    peptide    stem    plays    chronic    glioblastoma    potency    coreceptor    inflammatory    tool    cardiovascular    antagonists    antagonist    linked    progenitor    pave    identification    inflammation    suggest    entry    derivatives    arthritis    entire    inhibitor    modulating    market    naturally    approved    x4    orders    amd3100    magnitude    mozobiol    human    migration    named    hematopoietic    reg    receptor    epi    showing    mobilizes    invasion    prospects    encompassing    albumin    small    disorders    chemokine    inhibits    asthma    parallel    plasma    cancers    signaling    lung    colon    peptidome    blocks    preclinical    cell    models    screen    efficient    deregulation    treatment    dermatitis    stability    endogenous    preliminary    perform    synthetic    remarkably    model    cells    carcinoma    tolerated    allowed    commercialization    mice    ligands    safe    suppresses    fragment    osteosarcoma    cxcl12    goals    rheumatoid    cxcr4    ipr    airway    cancer    occurring   

Project "EPI-X4Health" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAET ULM 

Organization address
address: HELMHOLTZSTRASSE 16
city: ULM
postcode: 89081
website: www.uni-ulm.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 149˙156 €
 EC max contribution 149˙156 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAET ULM DE (ULM) coordinator 95˙256.00
2    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 26˙950.00
3    UNIVERSITE DE STRASBOURG FR (STRASBOURG) participant 26˙950.00

Map

 Project objective

Deregulation of CXCL12 signaling via the CXCR4 chemokine receptor plays a key role in many diseases, including cancer, rheumatoid arthritis, chronic inflammation and cardiovascular disorders. Thus, agents modulating CXCR4 signaling offer many prospects for therapeutic development. CXCR4 is also a major coreceptor for HIV entry. Thus, we used HIV as tool to screen peptide libraries encompassing the entire blood peptidome for novel CXCR4 ligands. This approach allowed the identification of a small fragment of human serum albumin as potent HIV inhibitor. Remarkably, this naturally occurring peptide, named EPI-X4 (Endogenous Peptide Inhibitor of CXCR4), blocks CXCL12/CXCR4 signaling and suppresses cancer cell migration and invasion. Preclinical studies in mice show that EPI-X4 mobilizes hematopoietic stem/progenitor cells and inhibits lung inflammation in an asthma model. Preliminary analyses suggest that EPI-X4 is more specific and better tolerated than Mozobiol® (AMD3100), the only CXCR4 antagonist approved for clinical application. Recently, we developed synthetic derivatives of EPI-X4 showing about three orders of magnitude improved potency against HIV as well as increased plasma stability. Key goals of this project are to determine the therapeutic potential of these improved derivatives against cancers (Aim 1) and inflammatory diseases (Aim 2) using established mouse models of colon carcinoma, osteosarcoma, glioblastoma, airway inflammation and dermatitis. These disorders were selected from the large number of CXCR4-linked diseases because no safe and effective treatment exists and since preclinical mouse models are available to determine whether EPI-X4 derived agents are more efficient and better tolerated than other compounds. In parallel to the experimental assessment of the therapeutic potential of these novel CXCR4 antagonists, we will perform market analyses and develop an IPR strategy to pave the way towards commercialization and future clinical application.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPI-X4HEALTH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPI-X4HEALTH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SUExp (2018)

Strategic Uncertainty: An Experimental Investigation

Read More  

MitoGuide (2019)

Integration and adaptation of impaired mitochondrial fitness in orchestrating T cell dysfunction in the tumor microenvironment

Read More  

TOROS (2019)

A Theory-Oriented Real-Time Operating System for Temporally Sound Cyber-Physical Systems

Read More